文献速递垂体与肾上腺疾病

KCNJ5体细胞突变与单侧原发性醛固酮增多症患者更好的长期结局相关

KCNJ5 Somatic Mutations Are Associated With Better Long-term Outcomes in Patients With Unilateral Primary Aldosteronism.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在台湾原发性醛固酮增多症研究数据库中,2013至2017年接受肾上腺切除术并随访至2020年的358例单侧原发性醛固酮增多症患者中,188例(52.5%)携带KCNJ5体细胞突变;携带者术后1年完全临床缓解的几率更高(OR=1.98,P=.016),长期主要不良心脑血管事件和死亡风险更低(HR=0.46,P=.044)。

要点

  • 年轻、较低BMI、较低血钾和较大肿瘤体积是KCNJ5体细胞突变的潜在预测因素。
  • 携带KCNJ5体细胞突变者术后1年完全临床缓解的几率更高(OR=1.98,P=.016)。
  • 携带KCNJ5体细胞突变者长期MACCE和死亡风险更低(HR=0.46,P=.044)。

核心结论

  • 携带KCNJ5体细胞突变的单侧原发性醛固酮增多症患者肾上腺切除术后长期主要不良心脑血管事件和死亡风险更低,且更可能达到完全临床缓解,但获益受基线血钾、高血压病程、BMI、eGFR和残余高血压等因素影响。

研究设计与样本

  • 研究纳入台湾原发性醛固酮增多症研究数据库中2013至2017年接受肾上腺切除术的单侧原发性醛固酮增多症患者,随访至2020年,共358例(46.7%为男性,平均年龄51.3岁),其中188例(52.5%)携带KCNJ5体细胞突变。

主要发现

  • 年轻(OR=2.44,P=.001)、较低BMI(OR=2.04,P=.005)、较低血钾(OR=6.55,P<.001)和较大肿瘤体积(OR=2.05,P=.023)是KCNJ5体细胞突变的潜在预测因素。
  • 携带KCNJ5体细胞突变者术后1年完全临床缓解的几率更高(OR=1.98,P=.016)。
  • 携带KCNJ5体细胞突变者(HR=0.46,P=.044)、高血压病程较短者(HR=1.05,P=.008)和达到完全临床缓解者(HR=0.49,P=.036)主要不良心脑血管事件和死亡风险更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The association between KCNJ5 somatic mutations and long-term outcomes in patients with operated unilateral primary aldosteronism (uPA) is unclear. OBJECTIVE: To evaluate associations among KCNJ5 somatic mutations, clinical characteristics, incident long-term cardiovascular events, and all-cause mortality in patients with uPA after adrenalectomy in a large longitudinal population study. METHODS: We enrolled patients with uPA from the Taiwan Primary Aldosteronism Investigation database who had undergone adrenalectomy between 2013 and 2017 and followed them until 2020. The outcomes were achieving complete clinical success at 1 year after adrenalectomy, long-term major adverse cardiac and cerebrovascular events (MACCEs), and mortality. RESULTS: Of the 358 enrolled patients (46.7% men; mean age, 51.3 years), 188 (52.5%) harbored KCNJ5 somatic mutations. The baseline characteristics of younger age (odds ratio [OR] = 2.44; P = .001), lower body mass index (OR = 2.04; P = .005), lower potassium (OR = 6.55; P < .001), and larger tumor size (OR = 2.05; P = .023) were potential predictors of KCNJ5 somatic mutations. The patients with uPA who were operated on and harboring KCNJ5 somatic mutations were associated with a higher likelihood of complete clinical success at 1 year after adrenalectomy (OR = 1.98; P = .016). KCNJ5 somatic mutation carriers (hazard ratio [HR] = 0.46; P = .044), those with a shorter duration of hypertension (HR = 1.05; P = .008), and those who achieved complete clinical success (HR = 0.49; P = .036) had a lower risk of MACCEs and mortality. CONCLUSION: Patients with uPA harboring KCNJ5 somatic mutations had a lower risk of long-term MACCEs and mortality following adrenalectomy. These patients were more likely to achieve complete clinical success, which contributed to improved outcomes. However, the benefits were influenced by factors such as baseline potassium levels, hypertension duration, BMI, eGFR, and residual hypertension, highlighting the interplay of genetic and clinical factors in determining prognosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chan CK, Yang WS, Lin YH, et al. KCNJ5 Somatic Mutations Are Associated With Better Long-term Outcomes in Patients With Unilateral Primary Aldosteronism. J Clin Endocrinol Metab. 2025. PMID: 39785822. doi:10.1210/clinem/dgaf007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。